OPKO Health, Inc. (NYSE: OPK) today announced that it will present data on its long acting oxyntomodulin (MOD-6030) product on April 25, 2014 at the 7 th Diabetes Drug Discovery and Development Conference being held in Cambridge, MA. Company scientists will make an oral presentation discussing MOD-6030, the company's long-acting GLP-1 and Glucagon dual agonist with potential for the treatment of type 2 diabetes and obesity. Pre-clinical data shows the drug induced a marked weight loss and food intake inhibition in both animal models which were superior compared to those with bi-daily injections of native OXM and to bi-daily injections of existing marketed drugs. The 7 th Diabetes Drug Discovery and Development Conference is being held April 23-25, in Cambridge, MA. For more information, visit: http://www.gtcbio.com/conference/diabetes-drug-discovery-and-development-overview. ABOUT OPKO HEALTH, INC. OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit http://www.opko.com.This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), regarding product development efforts and other non-historical facts about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects, including statements regarding our expectations about MOD-6030, whether MOD-6030 will induce marked weight loss and food inhibition or have superior performance compared to other drugs, and whether we will be able to successfully develop, obtain approval for and launch sales of MOD-6030. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that clinical trials for MOD-6030 may not be successful or achieve the expected results or effectiveness, and may not generate data that would support the approval or marketing of this product for the indications being studied, that others may develop products which are superior to MOD-6030, and that MOD-6030 may not have advantages or prove to be superior over presently marketed products. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.